These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23723597)

  • 1. Cosmeceuticals for Hyperpigmentation: What is Available?
    Sarkar R; Arora P; Garg KV
    J Cutan Aesthet Surg; 2013 Jan; 6(1):4-11. PubMed ID: 23723597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.
    Sofen B; Prado G; Emer J
    Skin Therapy Lett; 2016 Jan; 21(1):1-7. PubMed ID: 27224897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation.
    Ko D; Wang RF; Ozog D; Lim HW; Mohammad TF
    J Am Acad Dermatol; 2023 Feb; 88(2):291-320. PubMed ID: 35158001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Hydroquinone for Hyperpigmentation: A Narrative Review.
    Fabian IM; Sinnathamby ES; Flanagan CJ; Lindberg A; Tynes B; Kelkar RA; Varrassi G; Ahmadzadeh S; Shekoohi S; Kaye AD
    Cureus; 2023 Nov; 15(11):e48840. PubMed ID: 38106810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapies for melasma.
    Mahajan VK; Patil A; Blicharz L; Kassir M; Konnikov N; Gold MH; Goldman MP; Galadari H; Goldust M
    J Cosmet Dermatol; 2022 Sep; 21(9):3707-3728. PubMed ID: 35854432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Topical treatment of pigmentation disorders with cosmetic and pharmaceutical agents].
    Kerscher M; Buntrock H
    Hautarzt; 2020 Dec; 71(12):944-949. PubMed ID: 33146766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Over-the-counter Lightening Agent Use among Patients with Hyperpigmentation Disorders: A United States-based Cohort Study.
    Saade DS; Maymone MBC; Secemsky EA; Kennedy KF; Vashi NA
    J Clin Aesthet Dermatol; 2018 Jul; 11(7):26-30. PubMed ID: 30057662
    [No Abstract]   [Full Text] [Related]  

  • 8. Natural options for management of melasma, a review.
    Nomakhosi M; Heidi A
    J Cosmet Laser Ther; 2018; 20(7-8):470-481. PubMed ID: 29461133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Cosmeceutical Ingredients for Hyperpigmentation.
    Gonzalez N; Perez M
    J Drugs Dermatol; 2016 Jan; 15(1):26-34. PubMed ID: 26741379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The top 10 cosmeceuticals for facial hyperpigmentation.
    Searle T; Al-Niaimi F; Ali FR
    Dermatol Ther; 2020 Nov; 33(6):e14095. PubMed ID: 32720446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of systemic treatments for skin lightening.
    Juhasz MLW; Levin MK
    J Cosmet Dermatol; 2018 Dec; 17(6):1144-1157. PubMed ID: 30133125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Botanical Extracts in East Asia for Treatment of Hyperpigmentation: An Evidenced-Based Review.
    Hu S; Wolfe S; Laughter MR; Sadeghpour M
    J Drugs Dermatol; 2020 Jul; 19(7):758-763. PubMed ID: 32726104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation.
    Kolbe L; Mann T; Gerwat W; Batzer J; Ahlheit S; Scherner C; Wenck H; Stäb F
    J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():19-23. PubMed ID: 23205541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Insights in Melasma and Hyperpigmentation Management.
    Huerth KA; Hassan S; Callender VD
    J Drugs Dermatol; 2019 Aug; 18(8):718-729. PubMed ID: 31424704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin lightening preparations and the hydroquinone controversy.
    Draelos ZD
    Dermatol Ther; 2007; 20(5):308-13. PubMed ID: 18045355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lasers for treatment of melasma and post-inflammatory hyperpigmentation.
    Arora P; Sarkar R; Garg VK; Arya L
    J Cutan Aesthet Surg; 2012 Apr; 5(2):93-103. PubMed ID: 23060704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report on the use of topical cysteamine 5% cream in the management of refractory postinflammatory hyperpigmentation (PIH) resistant to triple combination cream (hydroquinone, topical corticosteroids, and retinoids).
    Mathe N; Balogun M; Yoo J
    J Cosmet Dermatol; 2021 Jan; 20(1):204-206. PubMed ID: 32997864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marine-Derived Compounds with Potential Use as Cosmeceuticals and Nutricosmetics.
    Alves A; Sousa E; Kijjoa A; Pinto M
    Molecules; 2020 May; 25(11):. PubMed ID: 32486036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of melasma with topical agents, peels and lasers: an evidence-based review.
    Rivas S; Pandya AG
    Am J Clin Dermatol; 2013 Oct; 14(5):359-76. PubMed ID: 23881551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies.
    Breathnach AS
    Cutis; 1996 Jan; 57(1 Suppl):36-45. PubMed ID: 8654129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.